Curated News
By: NewsRamp Editorial Staff
March 19, 2025
SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor at 2025 AACR Annual Meeting
Discuss on Reddit
LinkedIn
Telegram
GithubTLDR
- SignaBlok, Inc. to present positive preclinical oncology data on macrophage-restricted TREM-1 inhibitor, showcasing potential advantage in cancer treatment.
- SignaBlok's TREM-1 inhibitor prevents cancer recurrence, reverses immunosuppression, and showcases new mechanism-based peptide therapies for multiple diseases.
- SignaBlok's innovation in cancer treatment offers hope for improving complete response rate and survival, potentially benefiting patients with hard-to-treat solid tumors.
- SignaBlok's SCHOOL technology platform highlights a novel approach to inflammation treatment, promising new insights into cancer therapy and immune signaling.
Impact - Why it Matters
This news matters as SignaBlok's innovative approach could lead to improved treatments for pancreatic cancer and other solid tumors. The development of new therapies targeting inflammation-associated diseases could significantly impact patient outcomes and survival rates.
Summary
SignaBlok, Inc., a biotechnology company, will present positive preclinical oncology data on their macrophage-restricted TREM-1 inhibitor at the 2025 AACR Annual Meeting. The inhibitor shows promising results in experimental pancreatic cancer, improving response rates and survival. The company's SCHOOL technology platform is highlighted for its potential in clinical development.
Source Statement
This curated news summary relied on this press release disributed by 24-7 Press Release. Read the source press release here, SignaBlok to Present Positive Preclinical Data on TREM-1 Inhibitor at 2025 AACR Annual Meeting
